Home » Newsletters » BioWorld

BioWorld

Oct. 22, 1991

View Archived Issues

ONCOTECH CUTS PRICES ON CANCER TESTS

KININ BLOCKERS vs. SEPTIC SHOCK

PATENT TRIAL RESCHEDULED

IDEXX BUYS DIAGNOSTICS BUSINESS

ANTISENSE RNA STOPS RIPENING

FACTOR VIII MAb HELPS SUPPRESS AIDS

HUMAN TESTS OF BIOCINE'S AIDS VACCINE

SKIN REPLACEMENT TESTS SHOW PROMISE

ANTRIL'S PROMISE SPURS SYNERGEN STOCK

CANADIAN ALLIANCE TARGETS CANCER

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...